Physician profile
Mark U Liong
NPI 1346422078
$3,242.18
in general payments reported to CMS, 2019-2025
14 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2020: $114 · 2021: $274 · 2022: $580 · 2023: $708 · 2024: $649 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Education: $49.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.75 |
| Education | $49.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $1,305.21 | 2019-2025 | Auryxia, Vafseo |
| Astrazeneca Pharmaceuticals Lp | $835.73 | 2022-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $206.83 | 2022-2025 | Velphoro, Korsuva, Velphoro |
| Medtronic, INC. | $142.03 | 2024 | Ellipsys Vascular Access System |
| Vifor Pharma, INC. | $116.52 | 2019-2025 | Veltassa |
| Veloxis Pharmaceuticals, INC. | $112.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $102.10 | 2019 | |
| Mallinckrodt Hospital Products INC. | $98.12 | 2025 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $84.10 | 2025 | |
| Horizon Therapeutics Plc | $80.70 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Aurinia Pharma U.S., INC. | $55.99 | 2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $32.87 | 2023 | Tarpeyo |
| Travere Therapeutics, INC. | $8.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Liong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.